【レポートの概要（一部）】
1. Report Overview
1.1 Brazil: Pharmaceutical Market Overview
1.2 Brazilian Pharmaceutical Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Main Questions Answered by This Survey
1.6 Who is Our Report For?
1.7 Research and Analysis Methods
1.8 Frequently Asked Questions (FAQs)
1.9 Some Associated Reports
1.10 About Visiongain
2. Introduction to the Brazilian Pharmaceutical Market
2.1 The Brazilian Pharmaceutical Market Overview
2.2 Generics Segment Continues to Grow in Importance
2.3 CNS – The Largest Therapeutic Area in 2015
2.4 Four Domestic Companies in the Top Ten in 2015
3. The Significance of the Brazilian Market
3.1 Brazilian Economy is the Ninth Largest in the World
3.2 Brazil is the Eighth Largest Pharmaceutical Market
3.3 Brazil is the Largest Market in Latin America
3.4 Brazil Qualifies as a ‘Pharmerging’ Country and one of the BRIC Markets
4. Organisation of the Brazilian Pharmaceutical Market
4.1 ANVISA – Brazil’s Equivalent of the FDA
4.2 Other Influential Organisations
4.3 SUS – One of the World’s Largest Public Health Systems
4.4 Private Healthcare Accessed by 25% of the Population
4.5 Private Insurance Market Growing but Costs are Rising
4.6 New Drug Price Adjustment System Introduced
4.7 RENAME Drug Reimbursement System and the Farmácia Popular
4.8 Extensive Network of Pharmacies in Brazil
4.9 Wholesale and Retail Sectors Undergoing Consolidation
4.10 Panpharma is the Top Wholesale Distributor
4.11 Profarma is the Largest Mixed Distributor
4.12 Raia Drogasil is the Leader in the Retail Sector
4.13 Spending on Marketing Approaches $5bn
5. Major Differences in Healthcare Between Regions
5.1 Size and Prosperity of Different Regions
5.2 South-East is the Richest and Most Populous Region
5.3 South Has the Second Highest GDP
5.4 North-East Has the Second Highest Pharmaceutical Market Share
5.5 North is the Largest and Poorest Region
5.6 Mid-West is a Landlocked Region Housing the Nation’s Capital
6. Product Segments in the Brazilian Pharmaceutical Market 2016-2026
6.1 Forecasts for the Originator, Generic and OTC Segments 2015-2026
6.2 Originator Segment Will be Overtaken by Generics
6.2.1 Product Development Partnerships to Reduce Costs
6.2.2 Originator Drugs Threatened by 35% Cheaper Generics
6.3 Generics Drug Segment Forecast 2015-2026 – Continued Rapid Growth
6.3.1 Rapid Expansion of Generic Segment
6.3.2 Generic Companies Aiming for 45% Market Share
6.3.3 Similares Drugs Face Same Pricing Rules as Generics
6.3.4 Counterfeit Drugs Account for 20% of the Market
6.3.5 National Drug Security System to Tackle Counterfeit Drugs
6.3.6 Challenges for the Brazilian Generics Market
6.4 Brazilian Biologics Market
6.4.1 Biosimilars Market to Double in Size by 2017
6.4.2 BiocadBrazil Brings More Biosimilars to Brazil
6.5 OTC Drug Segment Forecast 2015-2026
6.5.1 Analgesics and Multivitamins Favoured by Brazilians
6.5.2 One Sixth of Population Buy Multivitamins
6.5.3 Restrictions on OTC Products Reversed
6.5.4 Consumer Health Treatments Remain Prominent in the Market
7. Therapeutic Areas of the Brazilian Market 2015-2026
7.1 Forecasts for CNS, Cardiovascular, Gastrointestinal/Metabolic, Oncology, Infectious Diseases and Other Therapeutic Areas, 2015-2016
7.2 The Rise of Non-Communicable Diseases
7.3 Market Forecast for CNS Conditions 2015-2026
7.3.1 CNS Conditions Currently the Largest Therapeutic Area
7.3.2 Domestic Companies Target Generic and OTC CNS Products
7.3.3 Foreign Companies Target Analgesics Market
7.3.4 One Fifth of Brazilians Have Suffered Depression
7.3.5 CNS Conditions: Drivers and Restraints
7.4 Market Forecast for Cardiovascular Therapeutic Area, 2015-2026
7.4.1 Rate of Cardiovascular Disease Expected to Triple
7.4.2 Almost One Quarter of the Population are Hypertensive
7.4.3 Statin Revenues Decline with Loss of Patent Protection
7.4.4 Domestic and International Companies Compete in CVS
7.4.5 Cardiovascular Opportunities and Challenges
7.5 Market Forecast for Gastrointestinal/Metabolic Therapeutic Area, 2015-2026
7.5.1 High Prevalence of Diabetes and GI Conditions
7.5.2 Low Awareness of Diabetes Amongst Population
7.5.3 Drive for Domestic Production of Insulin
7.5.4 EMS’s Generic Esomeprazole an Important Addition
7.5.5 Capturing the Gastrointestinal/Metabolic Disease Opportunity
7.6 Market Forecast for Oncology Therapeutic Area, 2015-2026
7.6.1 Cancer Treatment to Become the Leading Therapeutic Area
7.6.2 Increased Coverage of Cancer Care by Private Health Insurance Providers
7.6.3 What are the Commonest Cancers in Brazil?
7.6.4 Biosimilars Will Help Widen Access to Cancer Drugs
7.6.5 Cristália and Libbs Amongst Leading Oncology Companies
7.6.6 Promising Potential of the Oncology Therapeutic Area
7.7 Market Forecast for Infectious Diseases Therapeutic Area, 2015-2026
7.7.1 Vaccines and Antibiotics Lead Therapeutic Area
7.7.2 Brazil Increasingly Manufacturing its Own Vaccines
7.7.3 First Vaccination Programme Against Dengue Fever
7.7.4 Free Access to HIV Care Despite Concerns About Patent Protection
7.7.5 Chagas Disease and Other Tropical Infections
7.7.6 Long-Term Threat From Zika Virus Epidemic
7.7.7 Importance of Infectious Diseases Compared to Chronic Diseases
7.8 Market Forecast for Other Therapeutic Areas, 2015-2026
8. Domestic Companies in the Brazilian Market
8.1 The Top Ten Domestic Pharmaceutical Companies in 2015
8.2 Multinational Companies Still Own the Majority of the Market
8.3 Domestic Sector Actively Encouraged by Government
8.4 Domestic Firms Control 70% of Generics Market
8.5 EMS: Brazil’s Leading Pharmaceutical Company
8.5.1 Separate Divisions for Different Drug Categories
8.5.2 Full Production and R&D Capability
8.5.3 Legrand and Germed are Key Subsidiaries
8.5.4 Targeted Expansion Overseas
8.6 Hypermarcas: Market Leader in OTC and Branded Generics
8.6.1 Neo Quimica: Ranked Third in the Generics Segment
8.6.2 Subsidiaries Include Mantecorp and Brainfarma
8.7 Medley: Generics Company Owned by Sanofi
8.8 Aché: A Major Acquisition Target in Brazil
8.8.1 Anti-Inflammatory Acheflan Was First Drug Developed in Brazil
8.8.2 Involvement of Aché in Acquisitions Process
8.8.3 Part of Bionovis Collaboration
8.9 Eurofarma: Fifth Largest Domestic Company with Plans to Cover 90% of Latin America
8.9.1 Policy to Make Acquisitions in Latin America
8.10 Teuto Operates Largest Pharmaceutical Complex in Latin America
8.10.1 Melcon Partnership and Other Growth Strategies for Teuto
8.11 Biolab Farmaceutica Leads Cardiology Drugs Market
8.11.1 Partnering With German and Indian Companies
8.11.2 Current Pipeline and Product Launches
8.12 Cristalia: Largest Producer of Anaesthetics in Latin America
8.12.1 Approval from ANVISA to Produce Biosimilar Drugs
8.12.2 Leader in API Manufacturing
8.12.3 Involved in One Third of all PDPs
8.13 Libbs: Key Player in Cancer Treatment
8.13.1 Libbs Secures $106m in Funding from BNDES for New Biotechnology Facility
8.14 União Quimica: Huge Annual Production Capacity
8.14.1 Agreement with Novartis and Possible Public Offering in 2015
8.15 Other Domestic Players Include Laboratório Daudt Oliveira and Hebron
8.16 Biosimilar Collaborations
8.16.1 Bionovis: Conglomerate Developing 8 Biosimilars
8.16.2 Orygen: Conglomerate Aiming to Develop 7 Biologics
8.16.3 Other Biotech Players Include Biomm and Innova
8.16.4 Fiocruz: At the Heart of Multiple PDPs
8.16.5 ANVISA Reform of Brazilian Patent System
9. Multinational Companies in the Brazilian Market
9.1 The Top Ten Multinational Pharmaceutical Companies in Brazil, 2015
9.2 Notable M&A Activity
9.3 Sanofi: Medley Purchase Makes French Giant the Outright Leader
9.3.1 Group Companies Include Sanofi Pasteur and Genzyme
9.3.2 Inventory Mishandling and Dip in 2013 Results
9.4 Novartis: Only Multinational to Produce APIs in Brazil
9.4.1 PDPs and a New $342m Biotechnology Facility in the North East
9.4.2 Pricing and Reimbursement Solutions to Bring Costlier Drugs to Brazil
9.4.3 Investment in Expansion Plans
9.5 Roche: No Regrets About Staying in Brazil
9.5.1 Oncology Opportunity and Herceptin Pricing
9.6 Merck & Co. – Long-Standing Presence in the Brazilian Market
9.6.1 Five Factories and Five Broad Therapeutic Areas
9.6.2 Gardasil Added to SUS in 2013
9.6.3 Joint Venture with Eurofarma and Cristalia
9.7 Pfizer: Pursuing Strategy to Acquire Domestic Manufacturers
9.7.1 Portfolio Ranges from Orphan Biologics to Multivitamins
9.8 Takeda: Expanding its Brazilian Business
9.8.1 Acquisitions of Nycomed and Multilab
9.9 Bayer: Brazil is its Fifth Largest Market
9.9.1 OTC is a Major Focus in Brazil
9.10 AstraZeneca Targets Latin America
9.10.1 Struggling with Loss of Exclusivity and Patent Infringement
9.11 Boehringer Ingelheim: Pain, Cardiovascular and Respiratory Drugs Bolster Strong National Portfolio
9.11.1 Looking to Acquire OTC Brands
9.11.2 Technology Transfer Deal for Parkinson’s Disease
9.12 Merck KGaA Signed PDP with Bionovis for 8 Biosimilars
9.12.1 Two Divisions and Multiple Therapeutic Fields
9.13 Other Notable Multinationals in Brazil
9.13.1 GSK: Vaccines and Technology Transfer Opportunities
9.13.2 Abbott: Humira to Face Biosimilar Challenge in Brazil?
9.13.3 Abbott: Generics and Diagnostics-Led Growth Strategy
9.13.4 Eli Lilly: Investing in Upgrading Pharmaceutical Packaging Facility
9.13.5 Bristol-Myers Squibb: Divesting its Brazilian OTC Portfolio Rights
9.13.6 Baxter Entering Haemophilia Market Via Technology Transfer
9.13.7 Johnson & Johnson: Focusing on Consumer Health and Commodities
9.13.8 BiocadBrazil Farmaceutica
9.13.9 Amgen Signals Brazilian Intent with Bergamo Acquisition
9.13.10 Gilead, Novo Nordisk, Biogen, UCB and Meizler
9.13.11 Other Top Japanese Companies Trail Behind Takeda in Brazil
9.14 Will Multinational Generics Leaders Compete in Brazil?
9.14.1 Teva Targets Brazil
9.14.2 Mylan Acquires Agila to Boost Brazilian Strategy
9.14.3 Actavis May Target Brazil
9.14.4 Ranbaxy and Daiichi Sankyo
9.14.5 Torrent, Glenmark, Strides Arcolab and Biocon Looking to Brazil
9.14.6 Valeant: M&A Drive Into the Market
9.15 Brazil as a Pharmaceutical Research Destination
10. Qualitative Analysis of the Brazilian Pharmaceutical Market, 2016
10.1 Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis
10.1.1 A Crucial Market for the Pharmaceutical Industry
10.1.2 Government Regulation Remains an Issue
10.1.3 One of the Highest Pharmaceutical Tax Rates in the World
10.1.4 Room to Expand in Therapeutic Areas and Geographic Regions
10.1.5 Technology Transfer Uncertainties, IP Protection Doubts and Counterfeiting Issues
10.2 Social, Technological, Economic and Political (STEP) Analysis
10.2.1 Large and Ageing Population Eager to Buy Medicines
10.2.2 Shortcomings of Brazil’s Healthcare System
10.2.3 Government Aims for Greater Self-Sufficiency in Biotechnology and Health IT
10.2.4 Can Economic Growth Keep Pace with Healthcare Costs?
10.2.5 Political Environment Acts as Decisive Influence on the Market
10.2.6 Will BREXIT Affect Free Trade Negotiations with the EU?
11. Research Interviews
11.1 Interview With Vitor Zani, Business Development Coordinator, BiocadBrazil Farmaceutica
11.1.1 On Gaining Access to the Brazilian Market
11.1.2 Factors That Differentiate Brazil From Other Markets
11.1.3 The Brazilian Generics and Biosimilars Market and Biocad’s Progress with Biosimilars
11.1.4 Biocad’s Brazilian Pipeline, its Progress in 2014 and its Prospects for the Future
11.1.5 Development of the Brazilian Pharmaceutical Market 2015-2025; Drivers for Growth and Opportunity in the North East
11.1.6 Effect of the 2014 World Cup on the Brazilian Pharmaceutical Market and How the 2016 Olympics Will Compare
11.1.7 Strengths and Weaknesses of the Brazilian Pharmaceutical Market and Whether the Weaknesses Will Improve in Coming Years
11.2 Interview with André Brazay, President of Sandoz Brazil
11.2.1 Impact of Current Political and Economic Situation
11.2.2 Challenges faced by Domestic Companies
11.2.3 How Generics Market in Brazil Differs from Other Countries
11.2.4 Importance of Biosimilars in Brazil
11.2.5 Factors for an Overseas Investor to Consider
11.2.6 Future Challenges for the Market in Brazil
12. Conclusions from Our Research and Analysis
12.1 Growth of Brazil’s Pharmaceutical Market Will Outstrip That of More Developed Countries
12.2 Generics Will be Major Driver of Growth
12.3 Technology Transfer Boosts Domestic Production of Originator Drugs
12.4 Generics Market Provides Alternative Option for Multinationals
12.5 Oncology is Leading Therapeutic and Commercial Opportunity
12.6 Concluding Comments
【レポート販売概要】
■ タイトル：医薬品のブラジル市場見通し2016-2026■ 英文：Brazilian Pharmaceutical Market Outlook 2016-2026
■ 発行日：2016年9月
■ 調査会社：visiongain
■ 商品コード：VGAIN60905
■ 調査対象地域：ブラジル
- 世界の肺炎球菌ワクチン市場（2014-2018）About Pneumococcal Disease and Its Prevention Pneumococcus (Streptococcus pneumonia), a pathogenic bacterium, is the leading cause of serious illness across the globe. It is the main cause of pneumonia, sinusitis, blood infections, meningitis, and middle ear infections (otitis media). Pneumococcal disease affects children and the elderly, and it is one of the leading infectious diseases worldwide. …
- 世界の手術台市場動向（2012-2016）TechNavio's analysts forecast the Global Operating Tables market to grow at a CAGR of 3.95 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in complex surgical procedures. The Global Operating Tables market has also been witnessing an increase in medical tourism. However, increasing budgetary constraints could pose a challenge to the grow …
- バイオ系建築用ポリマーの世界市場分析：製品別（セルロースアセテート、エポキシ、ポリエチレンテレフタレート（PET）、ポリウレタン）、用途別（パイプ、外郭、断熱）、セグメント予測The global bio based construction polymers market is expected to reach USD 33.26 billion by 2024 according to a new report by Grand View Research, Inc. Rising bio-based polymer demand in various applications in the construction sector such as cladding panel, FRP bridge section, and glazing sealant is expected to remain a key driving force for the market growth. Increasing regulatory intervention t …
- 魚加工の世界市場：冷凍魚、保存魚The global market for fish processing has been growing steadily during the last few decades. In terms of value, the market is projected to reach USD 222.71 Billion by 2021, at a CAGR of 3.8% from 2016 to 2021 and is projected to reach 37,194.98 KT in terms of volume by 2021, at a CAGR of 2.2%. Factors such as high nutritional profile and added health benefits of processed fish and fish products, g …
- プレミアムA2P及びP2Aメッセージングの世界市場予測（～2021年）MarketsandMarkets forecasts the premium A2P and P2A messaging market size to grow from USD 55.49 Billion in 2016 to USD 71.60 Billion by 2021, at a Compound Annual Growth Rate (CAGR) of 5.23% from 2016 to 2021. Increasing mobile subscriber base, indispensable requirement to have ubiquitous and direct personal communication channel for enterprises to interact with their customers, rising use of mob …
- 油圧ポンプの世界市場2017-2021About Hydraulic PumpsHydraulic pumps are devices that are used to generate energy in different machines. The pump takes in a fluid and uses the force of the fluid to produce energy that is used to power machines while the fluid is released. In this manner, the mechanical energy of the fluid is converted to hydrostatic energy. The mechanical action of the pump creates a vacuum and lets the atmosphe …
- 食品ナノテクノロジーの世界市場2019-2023About this market The global rise in population is one significant factor propelling the need for techniques to improve agricultural productivity. The rapid growth in population would encourage increased adoption of novel nanotechnology tools to boost agricultural productivity. This factor would be a significant growth factor for the global food nanotechnology market over the forecast period. Tech …
- 2014年戦略提言：イギリスの呼吸器病診断検査市場About This ReportThis new 281-page report from Venture Planning Group presents detailed analysis of the UK Respiratory Diseases market, including sales forecasts and supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales projections for Hospitals, Commercial and Public Health Labs.In additio …
- V503（ヒトパピローマウイルスワクチン）：市場予測と分析（～2022）V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022 Summary The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines w …
- 世界の機械保護ソリューション市場動向：Global Machine Safeguarding Solutions Market 2014-2018Machine safeguarding solutions are safety devices that reduce the potential risk that may arise due to faulty operation of a machine in a workplace or on a production line. They are aimed at developing a safe working environment for enhanced productivity. Thus, these solutions enable risk-free and safe applications such as assembly and disassembly, pressing, molding, fabrication, stamping, and for …
- 自動車OEM業界向け工場内物流の世界市場2018-2022About In-plant Logistics for Automobile OEM Industry The global in-plant logistics market for automobile OEM industry refers to the movement of raw materials, components, and sub-assemblies within the automobile original equipment manufacturing plant, either to or from the storage area or line-sides, to be turned into finished goods and bringing them to the factory gate or a designated storage are …
- 食器洗い機の世界市場2016-2020About Dishwasher Dishwashers help in the cleaning and washing of dishes and utensils. There are two types of dishwashers: built-in dishwashers and freestanding dishwashers. Unlike freestanding dishwashers, built-in dishwashers are connected to the flow of other kitchen accessories. Dishwashers not only help save time but also reduce wastage of water and energy significantly. The increased populari …
- 世界における医療用・手術用レーザーの製品パイプライン動向2015Medical & Surgical Lasers - Pipeline Review, 2015 Summary GlobalData's Medical Devices sector report, “Medical & Surgical Lasers - Pipeline Review, 2015" provides an overview of Medical & Surgical Lasers currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews m …
- ラボラトリーサービスの世界市場：FE-TEM、STEM、FIB-SEM、FEG-SEM、SIMSService laboratory is a process of identifying faults and defects in the products. It is the most widely used process across several industries under high quality reliability platform. Service laboratory equipment helps in analyzing the root cause of failure of an end product, device, or system in order to develop corrective action plan. It helps in improving next generation versions of the produc …
- 医療用フットインソールの世界市場2018-2022About Medical Foot Insoles A foot insole is a foot orthotic device inserted into shoes to correct, align, prevent, and support the function of movable parts of the body and help with healing and reduction of pain in the feet. It is intended to correct the walkingpattern by aligning the angles at which the feet strike the ground. Medical foot insoles are used for patients with diabetes, accident vi …
